Dailey DL, Vance CGT, Van Gorp BJ, Johnson EM, Post AA, Chimenti RL, Vance KG, Franck C, Sault J, Yarasir E, Reisinger HS, Anderson A, Anderson J, Capelle R, Crouch A, Donatelle J, Kaster D, Kepros T, Nicklies E, Rein B, Worth R, Balinski M, Lafontant DE, Slade EJ, Jiang F, Ecklund D, Neill-Hudson T, Koepp M, Costigan M, Spencer M, Archer KR, Zimmerman BM, Bayman EO, Crofford LJ, Sluka KA
In February 2026, the FDA restricted GLP-1 APIs in non-approved compounded products, tightening enforcement in one area while, at the same time, Kennedys announcement committed to loosening access across 14 others
GLP-1 is viable for long-term use for patients who wish to lose excess weight
40 GLP-1RA: Effects of Obesity and Related Health Issues: Tirzepatide and semaglutide, unlike prior weight-loss drugs, are effective and relatively safe/well-tolerated medications that improve nearly all the negative health consequences of obesity
180ml/70pads
Semaglutide, a medication used to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, according to research presented at the AASLD virtual Liver Meeting
